164 related articles for article (PubMed ID: 27136467)
21. Clinical evaluation of M30 and M65 ELISA cell death assays as circulating biomarkers in a drug-sensitive tumor, testicular cancer.
de Haas EC; di Pietro A; Simpson KL; Meijer C; Suurmeijer AJ; Lancashire LJ; Cummings J; de Jong S; de Vries EG; Dive C; Gietema JA
Neoplasia; 2008 Oct; 10(10):1041-8. PubMed ID: 18813353
[TBL] [Abstract][Full Text] [Related]
22. [The role of tumour markers in diagnosis and management of testicular germ cell tumours].
Krege S; Albers P; Heidenreich A
Urologe A; 2011 Mar; 50(3):313-21. PubMed ID: 21327901
[TBL] [Abstract][Full Text] [Related]
23. Cell-free circulating DNA: diagnostic value in patients with testicular germ cell cancer.
Ellinger J; Wittkamp V; Albers P; Perabo FG; Mueller SC; von Ruecker A; Bastian PJ
J Urol; 2009 Jan; 181(1):363-71. PubMed ID: 19010497
[TBL] [Abstract][Full Text] [Related]
24. Elevated serum levels of IGF-binding protein 2 in patients with non-seminomatous germ cell cancer: correlation with tumor markers alpha-fetoprotein and human chorionic gonadotropin.
Fottner C; Sattarova S; Hoffmann K; Spöttl G; Weber MM
Eur J Endocrinol; 2008 Sep; 159(3):317-27. PubMed ID: 18524796
[TBL] [Abstract][Full Text] [Related]
25. May High Levels of Systemic Immune-Inflammation Index and Hematologic Inflammation Markers Suggest a Further Stage in Testicular Tumours?
Imamoglu GI; Eren T; Baylan B; Karacın C
Urol Int; 2019; 103(3):303-310. PubMed ID: 31466076
[TBL] [Abstract][Full Text] [Related]
26. Systemic inflammatory markers have independent prognostic value in patients with metastatic testicular germ cell tumours undergoing first-line chemotherapy.
Fankhauser CD; Sander S; Roth L; Gross O; Eberli D; Sulser T; Seifert B; Beyer J; Hermanns T
Br J Cancer; 2018 Mar; 118(6):825-830. PubMed ID: 29485982
[TBL] [Abstract][Full Text] [Related]
27. The search for biomarkers of metastatic seminoma.
Ruf CG; Khalili-Harbi N; Sachs S; Isbarn H; Wagner W; Matthies C; Meineke V; Fisch M; Chun FK; Abend M
J Urol; 2013 Sep; 190(3):1046-51. PubMed ID: 23583226
[TBL] [Abstract][Full Text] [Related]
28. [Tumor markers in testicular cancer].
Mann K
Urologe A; 1990 Mar; 29(2):77-86. PubMed ID: 2158684
[TBL] [Abstract][Full Text] [Related]
29. Can germ cell neoplasia in situ be diagnosed by measuring serum levels of microRNA371a-3p?
Radtke A; Cremers JF; Kliesch S; Riek S; Junker K; Mohamed SA; Anheuser P; Belge G; Dieckmann KP
J Cancer Res Clin Oncol; 2017 Nov; 143(11):2383-2392. PubMed ID: 28819887
[TBL] [Abstract][Full Text] [Related]
30. Significance of elevated preoperative alpha-fetoprotein in postchemotherapy residual tumor resection for the disseminated germ cell tumors.
Kobayashi T; Kawakita M; Terachi T; Habuchi T; Ogawa O; Kamoto T
J Surg Oncol; 2006 Dec; 94(7):619-23. PubMed ID: 17111392
[TBL] [Abstract][Full Text] [Related]
31. Significance of primary tumor size and preorchiectomy serum tumor marker level in predicting pathologic stage at retroperitoneal lymph node dissection in clinical Stage A nonseminomatous germ cell tumors.
Beck SD; Foster RS; Bihrle R; Donohue JP
Urology; 2007 Mar; 69(3):557-9. PubMed ID: 17382165
[TBL] [Abstract][Full Text] [Related]
32. Diagnostic value of markers AFP, HCG and LDH in advanced germ cell tumors before and after cytostasis resp.
Jaeger N; Vahlensieck W
Prog Clin Biol Res; 1985; 203():107-16. PubMed ID: 2421323
[No Abstract] [Full Text] [Related]
33. Lactate dehydrogenase and its isoenzymes in testicular germ cell tumors: an overview.
von Eyben FE
Oncodev Biol Med; 1983; 4(6):395-414. PubMed ID: 6196755
[TBL] [Abstract][Full Text] [Related]
34. The prognostic importance of neutrophil-to-lymphocyte ratio in testicular cancer.
Arıman A; Merder E
Urologia; 2021 Aug; 88(3):200-205. PubMed ID: 33568012
[TBL] [Abstract][Full Text] [Related]
35. Predictive value of modeled AUC(AFP-hCG), a dynamic kinetic parameter characterizing serum tumor marker decline in patients with nonseminomatous germ cell tumor.
You B; Fronton L; Boyle H; Droz JP; Girard P; Tranchand B; Ribba B; Tod M; Chabaud S; Coquelin H; Fléchon A
Urology; 2010 Aug; 76(2):423-9.e2. PubMed ID: 20472276
[TBL] [Abstract][Full Text] [Related]
36. Consensus statement on circulating tumour markers and staging patients with germ cell tumours.
Rustin GJ; Vogelzang NJ; Sleijfer DT; Nisselbaum JN
Prog Clin Biol Res; 1990; 357():277-84. PubMed ID: 2170994
[No Abstract] [Full Text] [Related]
37. Is relative quantification dispensable for the measurement of microRNAs as serum biomarkers in germ cell tumors?
Spiekermann M; Dieckmann KP; Balks T; Bullerdiek J; Belge G
Anticancer Res; 2015 Jan; 35(1):117-21. PubMed ID: 25550541
[TBL] [Abstract][Full Text] [Related]
38. Prosthetic valvular hemolysis: a potential pitfall in the routine use of serum lactate dehydrogenase as tumor marker in patients with germ cell testicular tumors.
Leibovitch I; Veinreb M; Sterenberg I; Alkalay R
Isr Med Assoc J; 2006 Sep; 8(9):659-60. PubMed ID: 17058425
[No Abstract] [Full Text] [Related]
39. Germ cell tumor in an adolescent with extensive testicular microlithiasis: concerns regarding future management.
Cambareri GM; Reiley EA; Hensle TW
Urology; 2013 Aug; 82(2):454-7. PubMed ID: 23566576
[TBL] [Abstract][Full Text] [Related]
40. Is gynecomastia related to the disease characteristics and prognosis in testicular germ cell tumor patients?
Polat AV; Öztürk M; Çamlıdağ İ; Akyüz B
Diagn Interv Radiol; 2019 May; 25(3):189-194. PubMed ID: 31063146
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
